Stock events for Arcus Biosciences, Inc. (RCUS)
In the past six months, Arcus Biosciences reported Q3 2025 financial results and a pipeline update, completed a stock offering, reported Q4 and full-year 2025 financial results, presented positive casdatifan data, discontinued domvanalimab studies, filed a mixed shelf offering, and experienced a stock price surge and analyst upgrades.
Demand Seasonality affecting Arcus Biosciences, Inc.’s stock price
Demand for Arcus Biosciences' products and services is not subject to traditional seasonality. Demand is driven by factors such as the global burden of cancer, the increasing prevalence of chronic and complex conditions, advancements in cancer biology, and the ongoing need for more targeted and personalized therapies.
Overview of Arcus Biosciences, Inc.’s business
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing differentiated molecules and combination therapies for cancer, inflammatory, and autoimmune diseases. Its pipeline includes casdatifan (HIF-2α inhibitor), domvanalimab (anti-TIGIT antibody), quemliclustat (CD73 enzyme inhibitor), zimberelimab (anti-PD-1 antibody), etrumadenant (dual A2a/A2b adenosine receptor antagonist), AB598 (CD39 antibody), AB801 (AXL inhibitor), and an emerging inflammation and immunology portfolio.
RCUS’s Geographic footprint
Arcus Biosciences, Inc. is headquartered in Hayward, California, United States. While its direct operational footprint is primarily in the U.S., it is described as a "global biopharmaceutical company". Its strategic partnerships, particularly with Gilead Sciences, Inc., extend its potential market reach globally, as Gilead has a global commercial network spanning over 90 countries.
RCUS Corporate Image Assessment
Arcus Biosciences' brand reputation has been positively impacted by strong efficacy data for casdatifan and its robust cash position. The discontinuation of domvanalimab studies could be perceived negatively, but the company's strategic agility in redirecting resources demonstrates resilience.
Ownership
Arcus Biosciences, Inc. is primarily owned by institutional investors and its largest strategic partner, Gilead Sciences, Inc. Gilead Sciences Inc. is the largest individual shareholder, owning 25.07% of the company. Other major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Suvretta Capital Management, Llc.
